Praxis Precision Medicines, Inc. announced the pricing of its public offering of 2,212,000 shares of common stock at $260.00 per share, with expected gross proceeds of $575 million. The offering includes an option for underwriters to purchase an additional 331,800 shares. The offering is set to close on or about January 8, 2026. Piper Sandler, TD Cowen, Guggenheim Securities, and Truist Securities are acting as joint book-running managers for the offering. The offering is being made pursuant to a shelf registration statement on Form S-3ASR. Praxis has disclosed forward-looking statements regarding the offering and its future prospects, subject to various risks and uncertainties outlined in SEC filings.

Read more at GlobeNewswire: Praxis Precision Medicines, Inc. Announces Pricing of $575